Canada Life
ADMS

Canada Life’s Adamas Pharmaceuticals ADMS Stock Holding History

Canada Life’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,303
Closed -$16K – 2816
2019
Q1 		$16K Hold
2,303
– – ﹤0.01% 2381
2018
Q4 		$19K Hold
2,303
– – ﹤0.01% 2545
2018
Q3 		$46K Hold
2,303
– – ﹤0.01% 2415
2018
Q2 		$59K Buy
+2,303
New +$63.8K ﹤0.01% 2368

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Canada Life's ADMS Position: Q2 2019 in Review

Canada Life sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 2,303 shares — an estimated $16K sold.

Canada Life first reported a position in ADMS in Q2 2018 and held it in 4 quarters. The position peaked at $59K in Q2 2018. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • Canada Life reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Canada Life sold 2,303 Adamas Pharmaceuticals shares in Q2 2019, an estimated $16K.
  • Canada Life first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Canada Life's Adamas Pharmaceuticals position peaked at $59K in Q2 2018.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on Canada Life's 13F filing for Q2 2019, filed 31 Jul 2019.